Moderna vaccine's stock recorded high in May with Phase I data.

The positive result of the COVID-19 vaccine study conducted by Moderna, a biotechnology company resulted in a rise in its stock price.

The positive result of the COVID-19 vaccine study conducted by Moderna, a biotechnology company resulted in a rise in its stock price.The share price of Moderna Incorporation company raised 20 percent on May 18, 2020, after the announcement of positive results of a Phase I study of potential COVID-19 vaccine. The share price closed at a record of $87, a rise of 19.96 percent.

Earlier, Moderna has announced that its vaccine was able to produce antibodies for COVID-19 in Phase I and its plans for Phase 2 and 3 trails.

Reference links

Nasdaq

supports

Investing

supports

MarketWatch

supports

Have a question or correction on one of our fact-checks?

If you think a claim has been misjudged or requires correction, please send us evidence to support your error claim. We will revisit our evidence and verdict and conduct additional research to verify new information.

Fact Check of the Day

misleading

397 children were diagnosed with heart inflammation after receiving Pfizer’s COVID-19 vaccine in U.S.